Previously, Chris served state Medicaid pharmacy programs for 17 years in the Magellan Medicaid Administration (MMA) preferred drug list (PDL) program. In 2004, he began as a Clinical Account Manager, with responsibilities including the implementation and daily operation of supplemental rebate and PDL programs for multiple states. This position served as the foundation for his pharmacoeconomic analysis skills that would propel his career with MMA. Chris explained clinical and financial analysis in Pharmacy & Therapeutics (P&T) Committee meetings for over 200 PDL classes on an annual basis and would go on to lead P&T meetings for 17 states. He also contributed to MMA’s library of Therapeutic Class Reviews as a writer and editor.
In 2011, Chris was promoted to Director of Clinical Services for PDL programs at MMA. In this role, he added leadership for the PDL Clinical Account Manager team and responsibility for 15 state customer contracts for PDL services. As Director, Chris developed a number of regular reports that provided market context for both the rebate negotiation team, as well as state customers, that supported PDL recommendations. He took an active role with manufacturers to shape supplemental rebate strategy through clinical analysis and net pricing trends. This work extended into co-author status for the industry’s first trend report from the Medicaid fee-for-service net spend standpoint, the Magellan Rx Management Medicaid Pharmacy Trend Report, from the first edition in 2016 through 2020.